ReviewMetabolic brain disease2025
The role of arachidonic acid metabolites in major depressive disorder: mechanisms and therapeutic implications.
Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Arachidonic acid (AA) is an important omega-6 polyunsaturated fatty acid (PUFA) stored in esterified form within cell membrane phospholipids, and it is widely present in various cell types. The esterified AA on the inner surface of the cell membrane is primarily hydrolyzed by phospholipase A2 (PLA₂) into its free form. Subsequently, it is metabolized by cyclooxygenase (COXs), lipoxygenase (LOXs), and cytochrome P450 (CYP450) enzymes. The metabolites of AA include a range of bioactive mediators such as prostaglandins (PGs), epoxyeicosatrienoic acids (EETs), hydroxyeicosatetraenoic acids (HETEs), leukotrienes (LTs) and lipoxins (LXs). These metabolites play critical and diverse roles in cellular physiology and are implicated in the pathogenesis of major depressive disorder. This review delves into the molecular mechanisms by which arachidonic acid and its metabolites contribute to the development of major depressive disorder, providing new perspectives for the development of novel antidepressant therapies.
Indexed as
Identifiers
41196452What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.